Douglas L. Mayers

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Travis K. Warren, Robert Jordan, Michael K. Lo et al. · Nature · 2016 · 1.6K citations · Full text

Small Molecule Gs-5734, Rhesus Monkeys, Medicine +10

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy

John D. Baxter, Douglas L. Mayers, Deborah Wentworth et al. · AIDS · 2000 · 502 citations

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Charles B. Hicks, Pedro Cahn, David A. Cooper et al. · The Lancet · 2006 · 322 citations

Durable Efficacy, Treatment-experienced Hiv-1-infected Patients, Hiv/aids Counselling +13

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group

A J Japour, Douglas L. Mayers, Victoria A. Johnson et al. · Antimicrobial Agents and Chemotherapy · 1993 · 294 citations

Primary Immunodeficiency, Medicine, Drug Susceptibilities +15

Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus

Jody Lawrence, Douglas L. Mayers, Katherine Huppler Hullsiek et al. · New England Journal of Medicine · 2003 · 265 citations · Full text